Trials / Completed
CompletedNCT01919125
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants with varying degrees of hepatic impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDX719 | IDX719 supplied as 50 mg tablets. |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2013-08-08
- Last updated
- 2016-01-26
Source: ClinicalTrials.gov record NCT01919125. Inclusion in this directory is not an endorsement.